EIIPY U0/U3/32 Case 25-10606-LSS Doc 501 Page 1 of 5 Docket #0501 Date Filed: 09/03/2025

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

In re:

Chapter 11

LEISURE INVESTMENTS HOLDINGS LLC,

Case No. 25-10606 (LSS)

et al., 1

(Jointly Administered)

Debtors.

AFFIDAVIT OF PUBLICATION OF NOTICE OF DEADLINES FOR THE FILING OF PROOFS OF CLAIM, INCLUDING REQUESTS FOR PAYMENTS UNDER SECTION 503(b)(9) OF THE BANKRUPTCY CODE IN THE NEW YORK TIMES

This Affidavit of Publication includes the sworn statement verifying that the Notice of Deadlines for the Filing of Proofs of Claim, Including Requests for Payments Under Section 503(b)(9) of the Bankruptcy Code was published and incorporated by reference herein as follows:

1. In The New York Times on August 18, 2025, attached hereto as Exhibit A.

Due to the large number of Debtors in these chapter 11 cases a complete list of the Debtors is not provided herein. A complete list of the Debtors along with the last four digits of their tax identification numbers, where applicable, may be obtained on the website of the Debtors' noticing and claims agent at https://veritaglobal.net/dolphinco, or by contacting counsel for the Debtors. For the purposes of these chapter 11 cases, the address for the Debtors is Leisure Investments Holdings LLC, c/o Riveron Management Services, LLC, 600 Brickell Avenue, Suite 2550, Miami, FL 33131.



Exhibit A



620 8th Avenue New York, NY 10018 nytimes.com

PROOF OF PUBLICATION

August 18, 2025

I, Larnyce Tabron, in my capacity as a Principal Clerk of the Publisher of The New York Times, a daily newspaper of general circulation printed and published in the City, County, and State of New York, hereby certify that the advertisement annexed hereto was published in the editions of The New York Times on the following date or dates, to wit on.

8/18/2025, NY/NATL, pg B5

Larnyce Tabron

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

In re: LEISURE INVESTMENTS
HOLDINGS LLC, et al.,
Debtors.

Chapter 11
Case No. 25-10606 (LSS)
(Jointly Administered)

trusts who have a claim or potential claim against the Debtors that arose lofere each Debtor's Petition Date, as applicable, no matter how remote or contingent such right to payment or equitable remedy may be, including requests for payment under section 503(b)(9) of the Bankruptry Code, must file a proof of claim on or before 5:00 p.m. (prevailing Eastern Time) on or before September 15, 2025 (the Seneral Bar Date-). Governmental entities who have a claim or potential claim against the Debtors that arose before the Petition Date, no matter how remote or contingent such right to payment or equitable remedy may be, must file a proof of claim or potential claim against the Debtor state arose before the Petition Date, no matter how remote or contingent such right to payment or equitable remedy may be, must file a proof of claim and the proof of claim or potential claim against the Debtor state and the proof of claim and the proof of claim or potential claim against the Debtor state of the Signature of the Signatur

applicable, on or before any other Bar Date as set forth herein or by order of the Court1 either by (i) electronically through the Online Portal (available at https://veritaglobal.net/dolphinco) or (ii) U.S. mail, or other hand delivery system at the following address: The Dolphin Company Claims Processing Center, Co NCC doa Verita, 222 N. Pacific Coast Highway, Sufte 300, El Sequado, A90245, T. (888) 733-1434 (U.S. /Canada) or (310) 751-2633 (International).

NOTICE OF DEADLINES FOR THE FILING OF PROOFS OF CLAIM, INCLUDING REQUESTS FOR PAYMENTS UNDER SECTION 593(b)(9) OF THE BANKRUPTCY CODE
PLEASE TARK NOTICE OF THE FOLLOWING:

Deadlines for Filing Proofs of Claim. On August 5, 2025, the United States Bankrupts (Court for the District Of Delaware (the "Court") entered an order (Doctet No. 433) (the "Bar Date Order") establishing certain order). (Bit of proofs of the includion of the Court of the District Of Delaware (the "Court") entered an order (Doctet No. 433) (the "Bar Date Order") establishing certain order). (III) state the legal and factual basis for the alleged claim; Deadlines for Filing Proofs of Claim. On August 5, 2025, the builded an order [Docter No. 432] (the "Bar Date Order") estated an order [Docter No. 432] (the "Bar Date Order") establishing certain deadlines for the filing of proofs of claim, including requests for payment (with establishing certain deadlines for the filing of proofs of claim, including requests for payment (with establishing certain of the above captioned debtors and debtors in possession (collectively, the values excluding state of the state of the state of the above captioned debtors and debtors in possession (collectively, the values of the state of the

potential claim against the Debtors based on the Debtors' rejection of an executory contract or unexpired elase, no matter how remote or contingent such right to payment or equitable remedy may be must file a proof of claim on the later of (i) the General Bar Date, and (ii) 30 days after the lentry of an order approving the rejection of any executory contract or unexpired lease of the Debtors the Rejection Claim Bar Date*). ANY PERSON DOR ENITTY WHO FAILST OF ILE A PROOF OF CLAIM, NOR ENITORY ENDOR ON BENTOR WHO ARIST OF ILE A PROOF OF CLAIM, STALL NOT BETREATED AS A CREDITOR WITH RESPECT TO SUCH (LAIM FOR THE PURPOSES OF VOTING AND DISTRIBUTION ON ANY CHAPTER 11 PLAN.

CHAPTER 11 PLAN.

Elina a Proof of Claim. Each proof of claim must be filed, including supporting documentation, so as to be actually received by Veritia on on before the General Bar Date or the Governmental Bar Date (or, where

Sworn to me this 18th day of August, 2025

Shannon Schmidt Online Notary Public State of New York Nassau County Commission #: 01SC0033223 Commission Expires: 01/28/2029

Tariffs Set to Hit Ireland, Where U.S. Drugmakers Play 'Tax Games'

companies are in the United States. So are a majority of their laboratories, clinical trial sites and, crucially, sales. But many of these companies register only a tiny share of the profits in the United States, helping them lower

Forest Laboratories, owned by AbbVie, shifted profits to Ireland for the antidepressant Lexapro, Gilead Sciences with its hepatitis C treatment Sovaldi and Regeneron with the eye drug

their overall tax bill.

In the past three years, some of the largest drugmakers booked 91 percent of their profits overseas, on average, up from 76 percent in the mid-2010s, according to an analysis by Martin Sullivan, a tax economist who writes for the trade publication Tax Notes.

Technically, drugmakers don't have to put their manufacturing in Ireland in order to shift profits out of the United States. Still, the strategy often involves putting it there.

In recent months, as Mr. Trump threatened to impose punishing tariffs on medicines, most of the largest drugmakers announced plans to spend billions of dollars building or expanding U.S. fac-

This spring, while under the threat of tariffs, the American drugmaker Merck announced a change for its cancer medication Keytruda — the best-selling drug on the planet — which it produces mainly in Ireland. Next year, the company plans to begin shifting Keytruda production for American patients to the United States.

In the meantime, Merck and others have scrambled to transport medicines while they could still flow freely. In the first five months of this year, shipments of pharma products from Ireland to the United States were up nearly fourfold compared with the same period in 2024. Merck said it had shuttled enough Keytruda to the United States to supply American patients for the rest of the year.

Irish trade data shows that about \$35 billion worth of ingredients used in weight-loss drugs were exported out of Ireland in the first three months of this year. The bulk of those shipments were from Eli Lilly, which manufactures active ingredients for its popular obesity drug Zepbound in

Unlike India and China, where local companies manufacture lowcost generics. Ireland is where the world's biggest drugmakers produce expensive brand-name medicines.

In County Cork, an industry hotbed in southwestern Ireland. Johnson & Johnson manufactures cancer medication, and Stelara, which treats conditions like arthritis. At a facility a few hours north, in County Mayo, AbbVie formulates Botox.

Last year, Ireland sent \$50 billion worth of pharma products to the United States, most of which were made and shipped by multinational drug companies. This relationship has provoked the ire of

the Trump administration. The president complained in March that Ireland's tax policies "took our pharmaceutical companies away." He added, "This beautiful island of five million people has got the entire U.S. pharma-

ceutical industry in its grasp." Howard Lutnick, the commerce secretary, said in an interview the same month that Ireland was running a "tax scam" that American tech and pharma companies were exploiting.

Tax experts and pharmaceutical executives have said that tariffs would be at best a blunt instrument for discouraging corporate activity in Ireland. Changing U.S. tax rules could more directly address the incentives that are motivating drugmakers, they said.

Lower tax rates overseas "drove a lot of the innovative companies to make drugs in low-tax islands like Ireland and Singapore and Switzerland," said David Ricks, chief executive of Eli Lilly. He called for lower tax rates for companies making products in the United States.

It remains to be seen whether tariffs and new U.S. factories will spur drugmakers to book more profits $-\bar{}$ and pay more taxes $-\bar{}$ in the United States. Where a company holds its intellectual property is more important for its tax bill than the location of its manufacturing, tax experts said.

Nearly all of the largest pharma companies have a manufacturing presence in Ireland, in some cases dating back decades.

The Irish government attracted drug companies by rewarding them for building factories and hiring local workers. The companies got not only tax advantages but also a skilled, English-speaking work force and easy access to the European market.

Ireland, in turn, gained highpaying jobs, new factories and billions of euros in taxes that helped create an enormous budget surplus. Today, a vast majority of Ireland's corporate tax revenue



A Johnson & Johnson plant in County Cork, Ireland, where the pharma giant manufactures active ingredients for Darzalex, a cancer medication, and Stelara, which treats conditions like arthritis.





A Merck manufacturing plant, left, in Swords, a suburb of Dublin. At right, an AbbVie facility in County Cork. Last year, Ireland sent \$50 billion worth of pharma products to the United States.

It's not a good situation to be in. But it could have been a lot worse.

Neil McGowan, an Irish union organizer, on the planned 15 percent tariffs on medicines.

comes from multinational drug companies and tech giants, which have also used Ireland to shift profits.

Many large American drugmakers have complex webs of subsidiaries around the world, including in Ireland. In a typical arrangement, the Irish subsidiary and its parent company enter into a licensing deal: The subsidiary gets to exploit a drug's intellectual property, for instance by funding research. The subsidiary pays the parent company royalties but keeps most of the profits - often billions of dollars a year.

This arrangement has allowed pharmaceutical companies to move profits out of Ireland and book them in tax havens like Bermuda or the Cayman Islands, which impose no income taxes at all, and where companies have no

actual business activity. Over the past decade, global tax authorities have increasingly cracked down on such tactics. It is not clear how much the practices have abated.

Irish officials said their country should not be dismissed as a tax shelter, pointing to the tens of thousands of Irish workers employed by multinational pharma companies. "If it was a tax scam, then those people wouldn't be working," said Daniel Mulhall, a former Irish ambassador to the United States.

There was some sense of relief in Ireland that the 15 percent tariff was not higher, said Neil McGowan, an organizer for an Irish union that represents thousands of pharmaceutical workers. "It's not a good situation to be in," he said. "But it could have been a lot worse." In the longer term, he said, "there are still concerns about what it's going to mean for people working in the industry

Drugmakers are expected to keep at least some of their manufacturing in Ireland regardless of the tariffs. But European Union officials, worried about the bloc's No. 1 export to the United States,



An infusion of the cancer drug Keytruda in 2014. Merck plans to shift some Keytruda production to the United States.

fear that drugmakers will cut jobs or cancel or scale back planned expansions.

For Keytruda, which is given as an intravenous infusion, a Merck

factory in the Dublin suburb Swords makes the active ingredients. An hour away in Carlow, another Merck plant handles the next step of formulating the drug,

according to the supply chain analytics firm QYOBO.

Johanna Herrmann, a spokeswoman for the company, said no job cuts were being planned at

Merck's Irish plants, which will continue to make Keytruda for countries other than the United States, along with other drugs.

Merck recently broke ground on a factory in Delaware that is expected to begin making Keytruda in 2030. Until then, the company says, U.S. contract manufacturers will handle production for American patients.

Plans to shift more of Merck's production to the United States were underway long before talk of tariffs, Ms. Herrmann said.

Merck has been reaping tax benefits from producing Keytruda in Ireland. But Keytruda somewhat deviates from the typical industry playbook, in which American companies move their intellectual property overseas so they can shift their profits.

Ms. Herrmann said that the patents protecting Keytruda have always been held in the Netherlands, where the drug was discovered in the 2000s before Merck acquired it. As a result, while three-fifths of Keytruda sales have been in the United States, Merck has booked much of the profits in the Netherlands.

Susan C. Beachy contributed re-

DISTRICT OF NEW JERSEY Chapter 11 Case No. 25-14861 (MBK) (Jointly Administered) NEW RITE AID, LLC, et al.

NEW RITE AID, LLC, et al., Debtors.\footnote{Index. as No. 25-14861 (MBK) (Jointly Administered)

NOTICE OF ELECTION DEADLINE

FOR THE SETTLEMENT OF ADMINISTRATIVE CLAIMS

PLEASE TAKE NOTICE THAT on August 14, 2025, the United States Bankrupts (out for the District of New Jersey (the "Bankrupts (Court")" entered an order [Docket No. 1883] (the "Administrative Claims Procedures; (b) authorizing the above captioned debtors and its affiliated debtors and debtors in possession (collectively, the "Debtors"), to carry out the terms of the Administrative Claims Procedures; (d) approving the normal manner of the Election Form to be distributed to Administrative Claims Procedures; (and the special proving the form and manner of the Election Form to be distributed to Administrative Claims 15; (e) scheduling certain dates with respect thereto; and (f) approving procedures for soliciting, receiving, and tabulating votes on the Administrative Claims Procedures.\footnote{1}

PLEASE TAKE FURTHER NOTICE THAT the Administrative Claims

1. Contact the Claims Agent at least three (3) business days before the Election Deadline by (a) emailing RiteAid2025Info@ rakroll.com (with 'In re New Rite Aid, LLC New Administrative Claimant Election Inquiry" in the subject line) or (b) through the Online Portal set forth at https://restructuring.rakroll.com/RiteAid2025. You should also contact your attorney if you have

| You may wish to consult a lawyer on how your rights, if any, may be affected by the Administrative Claims Procedures.

4. At your option, you may make an Opt-In Election or an Opt-Out Election by completing, signing, and returning your Election Form according to the instructions provided therein. The failure to follow the instructions on the Election Form may result in your election being disqualified.

5. Submit the completed and signed election form to the Claims Agent so that it is actually received by the Election Deadline (September 16, 2025 at 5:00 p.m. (prevailing Eastern Time)). Election Forms received after the Election Deadline will not be effective.

PLEASE TAKE FURTHER NOTICE THAT if you would like to obtain a

PLEASE TAKE FURTHER NOTICE THAT if you would like to obtain a debtor and debtors in possession (collectively, the "Debtors"), to carry out the terms of the Administrative Claims Procedures; (d) approving the form and manner of the Election Form to be distributed to Administrative Claims procedures in respect of the Administrative (Laims Procedures), and tabulating votes on the Administrative Claims Procedures.

PLEASE TAKE FURTHER NOTICE THAT the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims and the procedures of the Administrative Claims and the Administrative Claims and the procedures of the Administrative Claims and the procedures of the Administrative Claims and the Administrat

PLEASE TAKE FURTHER NOTICE THAT the Administrative Claims may elect to opt-in to or which certain holders of Administrative Claims may elect to opt-in to or which certain holders of Administrative Claims may elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims are the control of the certain holders of Administrative Claims are the certain ho op-out of the Administrative Claims Procedures.

PLEASE TAKE FURTHER NOTICE THAT by August 19, 2025, the Debtors shall cause the Administrative Claims in accordance with the Bankruptcy Code, the Bankruptcy Rules, the Administrative Claims in accordance with the Bankruptcy Code, the Bankruptcy Rules, the Administrative Claims Procedures.

The Claims Agent in accordance with the Claims In accordance with the Bankruptcy Code, the Bankruptcy Rules, the Administrative Claims in accordance with the Bankruptcy Code, the Bankruptcy Rules, the Administrative Claims Procedures.

The Claims Agent in accordance with the Claims In accordance om, wusatine@coleschotz.com, fyudkin@coleschotz.com, svanaalten@ coleschotz.com and -PAUL_WEISS, RIFKIND, WHARTON, svanaalten@ coleschotz.com and -PAUL_WEISS, RIFKIND, WHARTON, svanaalten@ coleschotz.com and -PAUL_WEISS, RIFKIND, WHARTON, SARRISDN OR OUT-OF THE SETTLEMENT PROPOSED IN THE ADMINISTRATIVE (LAIMS PROCEDURES, TOPARTICIPATE IN THE OPTIONAL ELECTION: Sean A. Mitchell (admitted *pro hac vice*), 285 Avenue of the Americas, New 1 (or New York 10019), elebone (212) 373-3000. Fassimile: (212) 757-York, New York 10019, Telephone: (212) 373-3000, Facsimile: (212) 757-3990, arosenberg@paulweiss.com, aeaton@paulweiss.com, chopkins@ paulweiss.com, smitchell@paulweiss.com, Co-Counsel for Debtors and

Debtors in Possession

The last four digits of Debtor New Rite Aid, LLCs tax identification
mumber are 1843. A complete list of the Debtors in these chapter 11 cases
and each such Debtor's tax identification number may be obtained on the
website of the Debtor's claims and noticing agent at https://restructuring.
rakvoll.com/Ritekid2025. The location of Debtor New Rite Aid, LLCs
principal place of business and the Debtors' service address in these
chapter 11 cases is 200 Newberry Common, Etters, Pennsylvania 17319.

Capitalized terms used but not otherwise defined herein shall have
the meanings given to them in the Administrative Claims Procedures Order.

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

In re: LEISURE INVESTMENTS Chapter 11 Case No. 25-10606 (LSS) HOLDINGS LLC, et al.,1 (Jointly Administered)

HOLDINGS LLC, et al., Case No. 25-10666 (LSS). Case No. 25-10666 (LSS). Case No. 25-10666 (LSS). Case No. 25-10666 (LSS). Control of the Debtors.

NOTICE OF DEADLINES FOR THE FILING OF PROOFS OF CLAIM, INCLUDING REQUESTS FOR PAYMENTS UNDER SECTION 930(b):90 THE BANKEN/TCY ODE PLEASETAKE NOTICE OF THE BOLDWING:

Deadlines for Filing Proofs of Claim, no August S. 2025, the United States Bankruptcy Court for the District of Delaware (the "Court") entered an order (Docket No. 433) (the "Bar Date Order, et al. and the case of the Petition Date and the original currency or in United States dollars as of the Petition Date (and the source appropriate under section 503(b)(9) of the Bankruptcy (ode, in the chapter 11 cases the above captioned debtors and debtors in possession (collective), the "Debtors").

The Bar Dates. Pursuant to the Bar Date Order, all entities (except yovernmental units), including individuals, partnerships, estates, and trusts who have a claim on potential claim against the Debtors Shared on the Petition Date, as applicable, no matter how remote or contingent such right to payment or equitable remedy may be, must file a proof of claim on a before \$5.00 p.m. (prevailing Eastern Time) on the date that is 180 days following the Petition Date applicable for each Debtors (The Governmental Bar Date"). All entities who have a claim on potential claim against the Debtors based on the Debtors Shared on any amendment by the Debtors of their Schedules, no matter how remote or contingent such right to payment or equitable remedy may be, if they so choose, must file a proof of claim on the later of (i) the General Bar Date"). All entities who have a claim on potential claim against the Debtors Shared on any amendment by the Debtors of their Schedules, no matter how remote or contingent such right to payment or equitable remedy may be, if they so choose, must file a proof of claim on the later of (i) the General Bar Date on the date of the Debtors Shared on any amendment by the Debtors is the Debtors Shared on t

applicable, on or before any other Bar Date as set forth herein or by order of the Court) either by (i) electronically through the Online Portal (available at https://veritaglobal.net/dolphinco) or (ii) U.S. mail, or other hand delivery system at the following address: The Dolphin Company Claims Processing Center, c/o KCC dba Verita, 222 N. Pacific Coast Highway, Suite 300, El Segundo, CA 90245, T. (888) 733-1434 (U.S./Canada) or (310) 751-633 (International)

Tariffs Set to Hit Ireland, Where U.S. Drugmakers Play 'Tax Games'

companies are in the United States. So are a majority of their laboratories, clinical trial sites and, crucially, sales. But many of these companies register only a tiny share of the profits in the United States, helping them lower

Forest Laboratories, owned by AbbVie, shifted profits to Ireland for the antidepressant Lexapro, Gilead Sciences with its hepatitis C treatment Sovaldi and Regeneron with the eye drug

their overall tax bill.

In the past three years, some of the largest drugmakers booked 91 percent of their profits overseas, on average, up from 76 percent in the mid-2010s, according to an analysis by Martin Sullivan, a tax economist who writes for the trade publication Tax Notes.

Technically, drugmakers don't have to put their manufacturing in Ireland in order to shift profits out of the United States. Still, the strategy often involves putting it there.

In recent months, as Mr. Trump threatened to impose punishing tariffs on medicines, most of the largest drugmakers announced plans to spend billions of dollars building or expanding U.S. fac-

This spring, while under the threat of tariffs, the American drugmaker Merck announced a change for its cancer medication Keytruda — the best-selling drug on the planet — which it produces mainly in Ireland. Next year, the company plans to begin shifting Keytruda production for American patients to the United States.

In the meantime, Merck and others have scrambled to transport medicines while they could still flow freely. In the first five months of this year, shipments of pharma products from Ireland to the United States were up nearly fourfold compared with the same period in 2024. Merck said it had shuttled enough Keytruda to the United States to supply American patients for the rest of the year.

Irish trade data shows that about \$35 billion worth of ingredients used in weight-loss drugs were exported out of Ireland in the first three months of this year. The bulk of those shipments were from Eli Lilly, which manufactures active ingredients for its popular obesity drug Zepbound in

Unlike India and China, where local companies manufacture lowcost generics. Ireland is where the world's biggest drugmakers produce expensive brand-name medicines.

In County Cork, an industry hotbed in southwestern Ireland. Johnson & Johnson manufactures cancer medication, and Stelara, which treats conditions like arthritis. At a facility a few hours north, in County Mayo, AbbVie formulates Botox.

Last year, Ireland sent \$50 billion worth of pharma products to the United States, most of which were made and shipped by multinational drug companies. This relationship has provoked the ire of

the Trump administration. The president complained in March that Ireland's tax policies "took our pharmaceutical companies away." He added, "This beautiful island of five million people has got the entire U.S. pharma-

ceutical industry in its grasp." Howard Lutnick, the commerce secretary, said in an interview the same month that Ireland was running a "tax scam" that American tech and pharma companies were exploiting.

Tax experts and pharmaceutical executives have said that tariffs would be at best a blunt instrument for discouraging corporate activity in Ireland. Changing U.S. tax rules could more directly address the incentives that are motivating drugmakers, they said.

Lower tax rates overseas "drove a lot of the innovative companies to make drugs in low-tax islands like Ireland and Singapore and Switzerland," said David Ricks, chief executive of Eli Lilly. He called for lower tax rates for companies making products in the United States.

It remains to be seen whether tariffs and new U.S. factories will spur drugmakers to book more profits $-\bar{}$ and pay more taxes $-\bar{}$ in the United States. Where a company holds its intellectual property is more important for its tax bill than the location of its manufacturing, tax experts said.

Nearly all of the largest pharma companies have a manufacturing presence in Ireland, in some cases dating back decades.

The Irish government attracted drug companies by rewarding them for building factories and hiring local workers. The companies got not only tax advantages but also a skilled, English-speaking work force and easy access to the European market.

Ireland, in turn, gained highpaying jobs, new factories and billions of euros in taxes that helped create an enormous budget surplus. Today, a vast majority of Ireland's corporate tax revenue



A Johnson & Johnson plant in County Cork, Ireland, where the pharma giant manufactures active ingredients for Darzalex, a cancer medication, and Stelara, which treats conditions like arthritis.





A Merck manufacturing plant, left, in Swords, a suburb of Dublin. At right, an AbbVie facility in County Cork. Last year, Ireland sent \$50 billion worth of pharma products to the United States.

It's not a good situation to be in. But it could have been a lot worse.

Neil McGowan, an Irish union organizer, on the planned 15 percent tariffs on medicines.

comes from multinational drug companies and tech giants, which have also used Ireland to shift profits.

Many large American drugmakers have complex webs of subsidiaries around the world, including in Ireland. In a typical arrangement, the Irish subsidiary and its parent company enter into a licensing deal: The subsidiary gets to exploit a drug's intellectual property, for instance by funding research. The subsidiary pays the parent company royalties but keeps most of the profits - often billions of dollars a year.

This arrangement has allowed pharmaceutical companies to move profits out of Ireland and book them in tax havens like Bermuda or the Cayman Islands, which impose no income taxes at all, and where companies have no

actual business activity. Over the past decade, global tax authorities have increasingly cracked down on such tactics. It is not clear how much the practices have abated.

Irish officials said their country should not be dismissed as a tax shelter, pointing to the tens of thousands of Irish workers employed by multinational pharma companies. "If it was a tax scam, then those people wouldn't be working," said Daniel Mulhall, a former Irish ambassador to the United States.

There was some sense of relief in Ireland that the 15 percent tariff was not higher, said Neil McGowan, an organizer for an Irish union that represents thousands of pharmaceutical workers. "It's not a good situation to be in," he said. "But it could have been a lot worse." In the longer term, he said, "there are still concerns about what it's going to mean for people working in the industry

Drugmakers are expected to keep at least some of their manufacturing in Ireland regardless of the tariffs. But European Union officials, worried about the bloc's No. 1 export to the United States,



An infusion of the cancer drug Keytruda in 2014. Merck plans to shift some Keytruda production to the United States.

fear that drugmakers will cut jobs or cancel or scale back planned expansions.

For Keytruda, which is given as an intravenous infusion, a Merck

factory in the Dublin suburb Swords makes the active ingredients. An hour away in Carlow, another Merck plant handles the next step of formulating the drug,

according to the supply chain analytics firm QYOBO.

Johanna Herrmann, a spokeswoman for the company, said no job cuts were being planned at

Merck's Irish plants, which will continue to make Keytruda for countries other than the United States, along with other drugs.

Merck recently broke ground on a factory in Delaware that is expected to begin making Keytruda in 2030. Until then, the company says, U.S. contract manufacturers will handle production for American patients.

Plans to shift more of Merck's production to the United States were underway long before talk of tariffs, Ms. Herrmann said.

Merck has been reaping tax benefits from producing Keytruda in Ireland. But Keytruda somewhat deviates from the typical industry playbook, in which American companies move their intellectual property overseas so they can shift their profits.

Ms. Herrmann said that the patents protecting Keytruda have always been held in the Netherlands, where the drug was discovered in the 2000s before Merck acquired it. As a result, while three-fifths of Keytruda sales have been in the United States, Merck has booked much of the profits in the Netherlands.

Susan C. Beachy contributed re-

DISTRICT OF NEW JERSEY Chapter 11 Case No. 25-14861 (MBK) (Jointly Administered) NEW RITE AID, LLC, et al.

NEW RITE AID, LLC, et al., Debtors.\footnote{Index. as No. 25-14861 (MBK) (Jointly Administered)

NOTICE OF ELECTION DEADLINE

FOR THE SETTLEMENT OF ADMINISTRATIVE CLAIMS

PLEASE TAKE NOTICE THAT on August 14, 2025, the United States Bankrupts (out for the District of New Jersey (the "Bankrupts (Court")" entered an order [Docket No. 1883] (the "Administrative Claims Procedures; (b) authorizing the above captioned debtors and its affiliated debtors and debtors in possession (collectively, the "Debtors"), to carry out the terms of the Administrative Claims Procedures; (d) approving the normal manner of the Election Form to be distributed to Administrative Claims Procedures; (and the special proving the form and manner of the Election Form to be distributed to Administrative Claims 15; (e) scheduling certain dates with respect thereto; and (f) approving procedures for soliciting, receiving, and tabulating votes on the Administrative Claims Procedures.\footnote{1}

PLEASE TAKE FURTHER NOTICE THAT the Administrative Claims

1. Contact the Claims Agent at least three (3) business days before the Election Deadline by (a) emailing RiteAid2025Info@ rakroll.com (with 'In re New Rite Aid, LLC New Administrative Claimant Election Inquiry" in the subject line) or (b) through the Online Portal set forth at https://restructuring.rakroll.com/RiteAid2025. You should also contact your attorney if you have

| You may wish to consult a lawyer on how your rights, if any, may be affected by the Administrative Claims Procedures.

4. At your option, you may make an Opt-In Election or an Opt-Out Election by completing, signing, and returning your Election Form according to the instructions provided therein. The failure to follow the instructions on the Election Form may result in your election being disqualified.

5. Submit the completed and signed election form to the Claims Agent so that it is actually received by the Election Deadline (September 16, 2025 at 5:00 p.m. (prevailing Eastern Time)). Election Forms received after the Election Deadline will not be effective.

PLEASE TAKE FURTHER NOTICE THAT if you would like to obtain a

PLEASE TAKE FURTHER NOTICE THAT if you would like to obtain a debtor and debtors in possession (collectively, the "Debtors"), to carry out the terms of the Administrative Claims Procedures; (d) approving the form and manner of the Election Form to be distributed to Administrative Claims procedures in respect of the Administrative (Laims Procedures), and tabulating votes on the Administrative Claims Procedures.

PLEASE TAKE FURTHER NOTICE THAT the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims with an option to elect to certain treatment in respect of such daims. For the specific terms and conditions of the Administrative Claims and the procedures of the Administrative Claims and the Administrative Claims and the procedures of the Administrative Claims and the procedures of the Administrative Claims and the Administrat

PLEASE TAKE FURTHER NOTICE THAT the Administrative Claims may elect to opt-in to or which certain holders of Administrative Claims may elect to opt-in to or which certain holders of Administrative Claims may elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims and elect to opt-in to or which certain holders of Administrative Claims are the control of the certain holders of Administrative Claims are the certain ho op-out of the Administrative Claims Procedures.

PLEASE TAKE FURTHER NOTICE THAT by August 19, 2025, the Debtors shall cause the Administrative Claims in accordance with the Bankruptcy Code, the Bankruptcy Rules, the Administrative Claims in accordance with the Bankruptcy Code, the Bankruptcy Rules, the Administrative Claims Procedures.

The Claims Agent in accordance with the Claims In accordance with the Bankruptcy Code, the Bankruptcy Rules, the Administrative Claims in accordance with the Bankruptcy Code, the Bankruptcy Rules, the Administrative Claims Procedures.

The Claims Agent in accordance with the Claims In accordance om, wusatine@coleschotz.com, fyudkin@coleschotz.com, svanaalten@ coleschotz.com and -PAUL_WEISS, RIFKIND, WHARTON, svanaalten@ coleschotz.com and -PAUL_WEISS, RIFKIND, WHARTON, svanaalten@ coleschotz.com and -PAUL_WEISS, RIFKIND, WHARTON, SARRISDN OR OUT-OF THE SETTLEMENT PROPOSED IN THE ADMINISTRATIVE (LAIMS PROCEDURES, TOPARTICIPATE IN THE OPTIONAL ELECTION: Sean A. Mitchell (admitted *pro hac vice*), 285 Avenue of the Americas, New 1 (or New York 10019), elebone (212) 373-3000. Fassimile: (212) 757-York, New York 10019, Telephone: (212) 373-3000, Facsimile: (212) 757-3990, arosenberg@paulweiss.com, aeaton@paulweiss.com, chopkins@ paulweiss.com, smitchell@paulweiss.com, Co-Counsel for Debtors and

Debtors in Possession

The last four digits of Debtor New Rite Aid, LLCs tax identification
mumber are 1843. A complete list of the Debtors in these chapter 11 cases
and each such Debtor's tax identification number may be obtained on the
website of the Debtor's claims and noticing agent at https://restructuring.
rakvoll.com/Ritekid2025. The location of Debtor New Rite Aid, LLCs
principal place of business and the Debtors' service address in these
chapter 11 cases is 200 Newberry Common, Etters, Pennsylvania 17319.

Capitalized terms used but not otherwise defined herein shall have
the meanings given to them in the Administrative Claims Procedures Order.

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

In re: LEISURE INVESTMENTS Chapter 11 Case No. 25-10606 (LSS) HOLDINGS LLC, et al.,1 (Jointly Administered)

HOLDINGS LLC, et al., Case No. 25-10666 (LSS). Case No. 25-10666 (LSS). Case No. 25-10666 (LSS). Case No. 25-10666 (LSS). Control of the Debtors.

NOTICE OF DEADLINES FOR THE FILING OF PROOFS OF CLAIM, INCLUDING REQUESTS FOR PAYMENTS UNDER SECTION 930(b):90 THE BANKEN/TCY ODE PLEASETAKE NOTICE OF THE BOLDWING:

Deadlines for Filing Proofs of Claim, no August S. 2025, the United States Bankruptcy Court for the District of Delaware (the "Court") entered an order (Docket No. 433) (the "Bar Date Order, et al. and the case of the Petition Date and the original currency or in United States dollars as of the Petition Date (and the source appropriate under section 503(b)(9) of the Bankruptcy (ode, in the chapter 11 cases the above captioned debtors and debtors in possession (collective), the "Debtors").

The Bar Dates. Pursuant to the Bar Date Order, all entities (except yovernmental units), including individuals, partnerships, estates, and trusts who have a claim on potential claim against the Debtors Shared on the Petition Date, as applicable, no matter how remote or contingent such right to payment or equitable remedy may be, must file a proof of claim on a before \$5.00 p.m. (prevailing Eastern Time) on the date that is 180 days following the Petition Date applicable for each Debtors (The Governmental Bar Date"). All entities who have a claim on potential claim against the Debtors based on the Debtors Shared on any amendment by the Debtors of their Schedules, no matter how remote or contingent such right to payment or equitable remedy may be, if they so choose, must file a proof of claim on the later of (i) the General Bar Date"). All entities who have a claim on potential claim against the Debtors Shared on any amendment by the Debtors of their Schedules, no matter how remote or contingent such right to payment or equitable remedy may be, if they so choose, must file a proof of claim on the later of (i) the General Bar Date on the date of the Debtors Shared on any amendment by the Debtors is the Debtors Shared on t

applicable, on or before any other Bar Date as set forth herein or by order of the Court) either by (i) electronically through the Online Portal (available at https://veritaglobal.net/dolphinco) or (ii) U.S. mail, or other hand delivery system at the following address: The Dolphin Company Claims Processing Center, c/o KCC dba Verita, 222 N. Pacific Coast Highway, Suite 300, El Segundo, CA 90245, T. (888) 733-1434 (U.S./Canada) or (310) 751-633 (International)